Toge T, Yamada Y, Ikeda H, Niimoto M, Hattori T
Gan. 1979 Oct;70(5):699-703.
The effect of chemo-immunotherapy on lymphocyte responsiveness to phytohemagglutinin (PHA) and pokeweed mitogen (PWM) was investigated in patients with advanced cancer. Patients received OK-432, a streptococcal preparation, intratumorally and additional systemic MFC (mitomycin-C, 5-fluorouracil, and cytosine arabinoside) chemotherapy intravenously. Patients with high lymphocyte responsiveness to mitogens at the beginning of treatment were more responsive to chemo-immunotherapy than those with low responsiveness. Furthermore, lymphocyte responsiveness to PHA was maintained at a high level throughout the treatment. In contrast, patients with initially depressed lymphocyte responsiveness maintained low responsiveness throughout the treatment. A significant increase of inhibitory activity of the serum was observed in patients with poor results of treatment. From these results, it seems reasonable to conclude that the response to chemo-immunotherapy might be predicted by in-vitro lymphocyte responsiveness.
研究了化疗免疫疗法对晚期癌症患者淋巴细胞对植物血凝素（PHA）和商陆有丝分裂原（PWM）反应性的影响。患者接受瘤内注射链球菌制剂OK-432，并静脉注射额外的全身MFC（丝裂霉素-C、5-氟尿嘧啶和阿糖胞苷）化疗。治疗开始时对有丝分裂原淋巴细胞反应性高的患者比反应性低的患者对化疗免疫疗法更敏感。此外，在整个治疗过程中，淋巴细胞对PHA的反应性维持在高水平。相比之下，初始淋巴细胞反应性降低的患者在整个治疗过程中反应性维持在低水平。治疗效果差的患者血清抑制活性显著增加。从这些结果来看，似乎有理由得出结论，化疗免疫疗法的反应可能可以通过体外淋巴细胞反应性来预测。
